ABBV 838Alternative Names: ABBV-838
Latest Information Update: 15 Nov 2016
At a glance
- Originator AbbVie
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action CD319 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Multiple myeloma
Most Recent Events
- 28 Oct 2016 AbbVie plans a phase Ib trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA, France, Spain and Australia (IV, Infusion) (NCT02951117)
- 01 May 2015 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (Parenteral)